ChemoCentryx (CCXI) Announces Significant Data from CCX872 In Vivo Models of NASH
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
ChemoCentryx, Inc., (Nasdaq: CCXI) announced the presentation of data from in vivo models of non-alcoholic steatohepatitis (NASH) with CCX872, a selective orally administered inhibitor of the chemokine receptor known as CCR2, at the American College of Gastroenterology (ACG) 2016 Annual Meeting, being held October 14-19, 2016.
The Company’s CCR2 inhibitor CCX872 demonstrated significant reductions in liver fibrosis when compared to either placebo or a separate compound which is a dual inhibitor of the chemokine receptors CCR2 and CCR5 currently in clinical development by another party. The data suggest a potential application of CCX872 for the treatment of patients with NASH, a severe type of non-alcoholic fatty liver disease caused by chronic inflammation that can lead to fibrosis (scarring) of the liver. NASH affects three to five percent of the U.S. population.
“Liver fibrosis is a critical and particularly difficult to treat feature of NASH, with considerable impact on long-term mortality and liver transplantation. We are therefore very pleased to see the therapeutic effect of our CCR2 inhibitor CCX872 improving liver fibrosis in NASH disease models,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “NASH is the fastest growing cause of liver cancer and liver transplant in the U.S. and other parts of the world; one for which there are no currently approved treatments. We look forward to sharing additional data from our efforts in this disease.”
Researchers believe that inhibiting CCR2 has several therapeutic benefits, including decreasing inflammatory macrophage infiltration into the liver, thus reducing hepatic inflammation and fibrosis. The data are being presented today in a poster titled “Reduction of Liver Fibrosis by CCR2 Antagonist CCX872 in Murine Models of NASH” (Abstract P2017, October 18, 10:30 a.m. to 4:00 p.m. PT) and are summarized as follows:
- CCX872 is a potent and highly selective inhibitor of CCR2, with a marked capacity to reduce the migration of the cells responsible for liver inflammation central to fibrosis in NASH.
- Two murine models of NASH were used to determine the efficacy of CCX872 in reducing fibrosis. One model used a high-fat diet (HFD) and the other model used a methionine-choline deficient diet (MCD), both of which are known to induce NASH.
- In both models, treatment with CCX872 achieved a statistically significant reduction in liver fibrosis as compared to placebo control.
- In the HFD model, there were statistically significant reductions in serum levels of alanine transaminase (ALT) and aspartate transaminase (AST), two key measures of liver injury, as well as reductions in the accumulation of inflammatory macrophages (which are derived from CCR2 precursor cells), and triglyceride and collagen content in the liver. Insulin sensitivity and glucose tolerance were also improved in the CCX872 treated group.
- In the MCD model, CCX872 achieved statistically significant reductions in serum ALT concentrations and liver and collagen content as compared to placebo control.
- In a side-by-side comparison in the murine MCD model, CCX872 was more efficacious than the CCR2/CCR5 dual inhibitor, which is elsewhere in clinical development, in reducing liver fibrosis.
- Overall treatment with selective CCR2 inhibitor CCX872 improved liver fibrosis in NASH pre-clinical models.
About Non-Alcoholic Steatohepatitis (NASH) and CCR2 InhibitionNASH is a severe type of non-alcoholic fatty liver disease (NAFLD) characterized by the accumulation of fat in the liver with no other apparent causes. NASH occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage. The inflammation can lead to fibrosis (scarring) of the liver and eventually progress to cirrhosis, portal hypertension, liver cancer, and eventual liver failure. Affecting three to five percent of the U.S. population, NASH is the fastest growing cause of liver cancer and liver transplant in the U.S. There are currently no approved treatments for NASH.
Liver fibrosis in NASH is caused by chronic inflammation with macrophage infiltration and cytokine production. Inflammatory macrophages express the chemokine receptor known as CCR2, which they use to migrate to the liver. CCX872 is the Company’s second-generation CCR2 inhibitor and has successfully completed Phase I studies in healthy volunteers with no serious adverse events. CCX872 is currently being evaluated in an on-going Phase Ib study for the treatment of non-resectable pancreatic cancer. In addition, a third-generation CCR2 inhibitor, CCX598, is poised to enter Investigational New Drug- (IND) enabling studies in 2017.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canadian Pacific Railway (CP) Names Keith Creel to Succeed as CEO
- Raytheon (RTN) Elects James Winnefeld Jr. to Board of Directors
- Immunomedics (IMMU): New IMMU-132 Data at Investor R&D Day
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!